Hamlet BioPharma says preclinical study shows oral BAMLET cuts weight gain, blood glucose in obesity, diabetes models

• Hamlet BioPharma highlighted new preclinical data on oral BAMLET, published Sept. 19, 2026 in Scientific Reports.
• Study found reduced weight gain, lower blood glucose, less adipose tissue growth in obesity and diabetes models; no effect in healthy mice.
• Intestinal barrier function improved within three days in a chronic diabetes model, supporting an intestine-focused mechanism.
• Researchers reported lower GLUT2 levels, inhibited glucose uptake, altered adiponectin and leptin signaling, pointing to multi-pathway metabolic effects.
• Commercial strategy targets nutrition products first, while Linnane Pharma advances development under a license that pays a 25% royalty through 2044.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hamlet Biopharma AB published the original content used to generate this news brief via Cision (Ref. ID: 202609211047BITN____UKPR__EN_20260921-BIT-3364-0) on September 21, 2026, and is solely responsible for the information contained therein.